Eli Lilly and Co (MIC:LLY-RM) Cyclically Adjusted Revenue per Share: ₽0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Eli Lilly and Co Cyclically Adjusted Revenue per Share?

Eli Lilly and Co MIC:LLY-RM 96 Cyclically Adjusted Revenue per Share is ₽0.00 as of Mar. 2026. GuruFocus rates MIC:LLY-RM with a GF Score™ of 96/100. The stock has 6 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share for the three months ended in Mar. 2026 was ₽1,796.452. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₽0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Eli Lilly and Co's average Cyclically Adjusted Revenue Growth Rate was 19.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Eli Lilly and Co was 12.00% per year. The lowest was 1.80% per year. And the median was 7.50% per year.

As of today (2026-07-24), Eli Lilly and Co's current stock price is ₽0.00. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₽0.00. Eli Lilly and Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eli Lilly and Co was 31.37. The lowest was 3.23. And the median was 9.70.


Eli Lilly and Co  (MIC:LLY-RM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eli Lilly and Co was 31.37. The lowest was 3.23. And the median was 9.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Eli Lilly and Co Cyclically Adjusted Revenue per Share Related Terms


Eli Lilly and Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted Revenue per Share Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MIC:LLY-RM vs JNJ, ABBV, MRK: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.



Eli Lilly and Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1796.452/330.2130*330.2130
=1,796.452

Current CPI (Mar. 2026) = 330.2130.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 325.354 241.018 445.760
201609 308.722 241.428 422.254
201612 326.688 241.432 446.820
201703 277.102 243.801 375.317
201706 327.386 244.955 441.335
201709 310.171 246.819 414.970
201712 179.995 246.524 241.099
201803 270.717 249.554 358.216
201806 340.640 251.989 446.384
201809 338.880 252.439 443.286
201812 383.771 251.233 504.417
201903 335.903 254.202 436.344
201906 384.421 256.143 495.586
201909 375.983 256.759 483.545
201912 413.846 256.974 531.794
202003 511.546 258.115 654.434
202006 422.450 257.797 541.118
202009 497.374 260.280 631.010
202012 606.400 260.474 768.757
202103 566.169 264.877 705.823
202106 544.183 271.696 661.387
202109 543.370 274.310 654.106
202112 638.910 278.802 756.725
202203 904.505 287.504 1,038.870
202206 452.673 296.311 504.465
202209 463.109 296.808 515.231
202212 493.792 296.797 549.387
202303 579.741 301.836 634.245
202306 747.315 305.109 808.803
202309 1,017.896 307.789 1,092.055
202312 933.674 306.746 1,005.103
202403 887.675 312.332 938.494
202406 1,130.030 314.175 1,187.716
202409 1,145.490 315.301 1,199.665
202412 1,612.240 315.605 1,686.864
202503 1,167.740 319.799 1,205.767
202506 1,343.924 322.561 1,375.805
202509 1,626.712 324.800 1,653.822
202512 1,707.650 324.054 1,740.106
202603 1,796.452 330.213 1,796.452

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₽0.00 mean?
Eli Lilly and Co (MIC:LLY-RM) has a Cyclically Adjusted Revenue per Share of ₽0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Cyclically Adjusted Revenue per Share too high?
Eli Lilly and Co's current Cyclically Adjusted Revenue per Share is ₽0.00. Overall, Eli Lilly and Co has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Cyclically Adjusted Revenue per Share compare to JNJ and ABBV?
Eli Lilly and Co's Cyclically Adjusted Revenue per Share of ₽0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Cyclically Adjusted Revenue per Share is ₽0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Eli Lilly and Co (MIC:LLY-RM) has a current Cyclically Adjusted Revenue per Share of ₽0.00. The current Cyclically Adjusted Revenue per Share is ₽0.00. Eli Lilly and Co's overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Eli Lilly and Co (MIC:LLY-RM), the current Cyclically Adjusted Revenue per Share is ₽0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.